- Liz Highleyman | 26 March 2014
An all-oral regimen of daclatasvir, asunaprevir and BMS-791325 – without
interferon or ribavirin – led to sustained response in approximately 90% of people
with hepatitis C virus (HCV) who had not previously ...
- Liz Highleyman | 21 March 2014
An all-oral combination of the hepatitis C virus (HCV) protease
inhibitor MK-5172 and NS5A inhibitor MK-8742, with or without ribavirin,
demonstrated promising end-of-treatment viral suppression in people with HIV
and HCV co-infection and ...
- Liz Highleyman | 21 March 2014
Antiretroviral therapy started during the first
several days after infection limited dissemination of an HIV-like virus
throughout the body and establishment of cellular and tissue reservoirs in
monkeys, but it did not prevent ...
- Liz Highleyman | 20 March 2014
Vaginal rings containing the experimental NNRTI
dapivirine were well tolerated and blocked HIV infection of cervical tissue
samples, but rings containing maraviroc did not produce adequate drug
concentrations, researchers reported at the 21st ...
- Liz Highleyman | 20 March 2014
Starting antiretroviral therapy (ART) at the earliest
stage of HIV infection can help prevent immune cell dysregulation that
contributes to destruction of the gut lining and promotes systemic immune
over-activation, according to a ...
- Gus Cairns | 19 March 2014
A
study from Orange Farm near Johannesburg in South Africa, the area that hosted the
first-ever randomised controlled trial of male circumcision for HIV prevention,
which concluded in 2005, has found evidence that ...
- Michael Carter | 18 March 2014
Up to 62% of people living with HIV who have high-grade pre-cancerous cell changes may experience
an improvement in their condition over two years without any treatment,
according to the results of ...
- Gus Cairns | 17 March 2014
One
of the first studies of open-label pre-exposure prophylaxis (PrEP) for at-risk
gay men in three US cities shows that although the proportion of those
initially offered or seeking PrEP who ended up ...
- Gus Cairns | 14 March 2014
The
nucleoside (NRTI) drug abacavir (Ziagen also in Kivexa/Epzicom)
continues to be associated with a near-doubling of the risk of a heart attack, according to the latest update from the Data
Collection on ...
- Liz Highleyman | 13 March 2014
An all-oral regimen of daclatasvir plus simeprevir,
without interferon or ribavirin, led to sustained response in 85 to 95% of people
with hepatitis C genotype 1b, but this combination did not work ...
- Carole Leach-Lemens | 12 March 2014
Pregnant women taking efavirenz-based antiretroviral therapy had significantly better virologic
outcomes at the time of delivery compared to those taking
lopinavir/ritonavir in a randomised study in rural Uganda, Dr Deborah
Cohan, reporting on ...
- Roger Pebody | 11 March 2014
Increasing the proportion of HIV-positive gay men in the UK
who have an undetectable viral load from the current figure of around 60% to 90% could result in a substantial drop ...
- Gus Cairns | 11 March 2014
A
study from Seattle has found that only having sex with men of the same HIV status was
by far the most common method of trying to avoid HIV in gay men ...
- Carole Leach-Lemens | 11 March 2014
Pregnant
women in Kenya have a similar risk of HIV infection during pregnancy to
serodiscordant couples or sex workers, Dr John Kinuthia told the 21st
Conference on Retroviruses and Opportunistic Infections (CROI) in ...
- Liz Highleyman | 11 March 2014
The
next-generation non-nucleoside reverse transcriptase inhibitor (NNRTI)
doravirine (formerly MK-1439) showed potent antiretroviral activity and good
tolerability in combination with tenofovir/FTC (the drugs in Truvada) in a dose-finding study
presented at the 21st Conference on Retroviruses and
Opportunistic ...
- Carole Leach-Lemens | 10 March 2014
Lopinavir/ritonavir
(Kaletra) or 3TC (lamivudine, Epivir) proved equally protective as infant prophylaxis
against HIV infection during 12 months of breastfeeding, Dr Chipepo Kankasa,
presenting on behalf of the ANRS 12174 trial, told participants ...
- Gus Cairns | 10 March 2014
A
number of studies at last week’s Conference on Retroviruses and Opportunistic Infections (CROI) examined whether people with
HIV had an elevated risk of heart attack and other manifestations of cardiovascular
disease. They ...
- Gus Cairns | 10 March 2014
The Conference on Retroviruses and Opportunistic Infections (CROI) this year heard a number of presentations on phylogenetic analysis – the use of genetic fingerprinting of HIV to trace patterns of ...
- Gus Cairns | 08 March 2014
An
oral combination therapy of two antiretroviral drugs, the non-nucleoside
rilpivirine (Edurant, also in Eviplera/Complera) and the new integrase
inhibitor GSK1265744 (744), was at least as effective as a standard nucleosides-plus-efavirenz
triple combination in ...
- Liz Highleyman | 07 March 2014
Genetically modified CD4 T-cells lacking CCR5 co-receptors reach high
levels in the body and are resistant to HIV infection, potentially enabling
people to maintain a low viral load while off antiretroviral therapy ...
Antiretroviral drug chartA one-page reference guide to the anti-HIV drugs licensed for use in the UK or European Union, with information on formulation, dosing, key side effects and food requirements.
Your next stepsA booklet with information for people who’ve just found
out they have HIV.
Coming soon: news from IAS 2019 05 July 2019The 10th International AIDS Society
conference (IAS 2019) is being held...
Those who are not seen are not heard 01 July 2019A commentary on Optimising the Impact of Key Population Programming...
The fight for access to abortion care in Europe 27 June 2019Access to
sexual and reproductive health and rights includes safe and...